SCHEMBL30206243

SCHEMBL30206243

CNc1nc(Nc2ccnc(OC)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGFBR1 P36897 7/20 0.33
▸ TGFBR2 P37173 5/20 0.33
▸ ACVR2A P27037 5/20 0.33
▸ WNT1 P04628 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ SYK P43405 2/20 0.32
▸ MAPK3 P27361 1/20 0.32
▸ TTK P33981 1/20 0.32
▸ CCNK O75909 1/20 0.31
▸ CCNA2 P20248 1/20 0.31
▸ CDK2 P24941 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ IRAK4 Q9NWZ3 1/20 0.30
▸ BUB1 O43683 1/20 0.30
▸ PIK3C3 Q8NEB9 1/20 0.30
▸ MAT2A P31153 1/20 0.30
▸ ABL1 P00519 1/20 0.30
▸ BCR P11274 1/20 0.30
▸ SRC P12931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173433 1.00 TGFBR1 (0.33) TGFBR1TGFBR2ACVR2AWNT1GSK3B
SCHEMBL30205492 0.93 EML4 (0.33) TGFBR1TGFBR2ACVR2AWNT1GSK3B
SCHEMBL24943808 0.93 EML4 (0.33) TGFBR1TGFBR2ACVR2AWNT1GSK3B
SCHEMBL29173658 0.91 BUB1 (0.34) TGFBR1SYKTTKBUB1PIK3C3
SCHEMBL30206107 0.86 CYP1A2 (0.35) TTKCCNA2CDK2SRC
SCHEMBL29173378 0.86 CYP1A2 (0.35) TTKCCNA2CDK2SRC
SCHEMBL30205968 0.85 HPGD (0.32) —
SCHEMBL29173474 0.85 HPGD (0.32) —
SCHEMBL29173448 0.82 SYK (0.36) SYK
SCHEMBL30206336 0.82 SYK (0.36) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 TGFBR1 3815/4885TGFBR2 4046/4885ACVR2A 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback